IncuBIO S.A.

206 Street, b/ 19 and 21
Postal code
Web page
Contact person's name
Einard Blanco García (General Director)
Short description of the company
INCUBIO S.A is a new company, founded in 2021 at the Mariel Special Development Zone, with the purpose to accelerate the development of innovative drugs in the field of neurodegenerative diseases by attracting equity investment. It's main asset is NeuroEPO, a clinically validated first-in-class drug to treat neurodegenerative diseases, including Alzheimer´s disease, Parkinson´s disease and`s description, links can be included)
Company`s description
NeuroEPO, is a clinically validated first-in-class drug to treat Alzheimer´s diseases. It is a patent protected recombinant protein obtained from a selected glycoforms of the less acid region of the recombinant human erythropoietin. NeuroEPO reaches pharmacological concentrations inside the brain, triggering both neuroprotective and neuro-regenerative mechanisms. Its brain activity mimics the one displayed by the endogenous erythropoietin, but without inducing systemic erythropoiesis, thus minimizing potential adverse events. Alzheimer’s patients treated with NeuroEPO showed a significant improvement on their cognitive and functional parameters during a randomized, controlled & double blinded, phase II/III clinical trial completed in Cuba. NeuroEPO is also being clinically evaluated as treatment for other neurodegenerative diseases as Parkinson´s and Ataxia. None other rhEPO variants being developed for Alzheimer´s disease have completed clinical trials yet.
Partner search
Equity Investors, Venture Capital, Big Pharma
Short content description
At INCUBIO S.A, investors have the opportunity to acquire shares and to increase its product(s) value by funding proof of concept clinical trials in major markets. IncuBIO holds IP commercializing rights for its asset’s in major markets (USA, CAN, EUR, JAP) and is seeking to receive financial investments through any of the following sources: - Non-dilutive funds. - Equity investment funds willing to acquire IncuBIO’s shares (Venture Capital). - Out-licensing to Big Pharma players.
The programme is co-financed by the Slovenian Enterprise Fund and the European Union, namely from the European Fund for Regional Development. It is carried out on the basis of the Substantial Support of Fund Recipients (SME) programme from 2018 to 2023 within the framework of the Operational Programme for the Implementation of European Cohesion Policy from 2014 to 2020.